Board of Directors

George F.J. Gosbee is interim chair of Arcadia’s board of directors and has served as a director since May 2015. He is the chairman and CEO of AltaCorp Capital. Prior to founding AltaCorp Capital in 2010, Mr. Gosbee was chairman, president and CEO of Tristone Capital Global Inc., a global energy investment firm that was acquired by an international bank in 2009. Mr. Gosbee is an alternate governor on the NHL Board of Governors and co-owner of the Arizona Coyotes. Mr. Gosbee was the vice chairman of Alberta Investment Management Co (AIMCo) which is a $90 billion institutional investment fund, and currently is a director. Mr. Gosbee is a former director of the TMX Group and a former board member of Chrysler Group LLC in Detroit, where he served on behalf of both the Canadian Federal and Provincial (Ontario) governments to oversee their collective investment in the company and assist in the restructuring. He holds a bachelor of commerce degree from the University of Calgary.

Kevin Comcowich joined the Arcadia board in October 2016. Mr. Comcowich brings extensive business and financial leadership experience and a proven track record of success in investment management and global capital market strategies. He most recently served as the chief executive officer and portfolio manager of HTX Energy Fund in Houston, Texas. He was previously the president and chief investment officer (CIO) of Sound Energy Partners and served as CIO and research analyst for Southport Energy Plus Partners fund. Mr. Comcowich received his MBA from the University of Indiana and earned his bachelor’s degree from the College of the Holy Cross.

Uday Garg has been a director of Arcadia since June 2014. Mr. Garg is the founder of Mandala Capital, a private equity fund, and has served as managing director and a director since its inception in 2008. Previously, he was a portfolio manager at Duet Group, Altima Partners and Amaranth Advisors, and began his career as an investment banker with Deutsche Bank. Mr. Garg holds a bachelor’s degree in economics with a concentration in finance from the Wharton School of Business at the University of Pennsylvania.

Raj Ketkar became a member of the board of directors in June 2016, after joining the company as president and chief executive officer in May 2016. He brings nearly 35 years of agriculture and agricultural biotechnology business experience in the U.S. and internationally, including more than 30 years in a variety of business, operations, and strategy roles for Monsanto Company. His positions included managing director of the Mahyco-Monsanto Biotech joint venture in India and director of biotechnology strategy. Mr. Ketkar holds a master’s degree in chemical engineering from Oklahoma State University and a master’s of business administration from the University of New Orleans.

Vic Knauf, Ph.D., joined the board of directors in February 2016. He is the former chief scientific officer at Arcadia, and has more than 30 years of experience in agricultural product and technology development to Arcadia. Dr. Knauf was the founder of Anawah, Inc., a food and agricultural research company that Arcadia acquired in 2005. Previously, Dr. Knauf was director of food and nutrition research for Monsanto Company and vice president of research at Calgene Inc., both agricultural companies. He holds a bachelor’s degree in biology from the New Mexico Institute of Mining and Technology, and master’s and doctorate degrees in microbiology and immunology from the University of Washington.

Rajiv Shah, M.D., joined Arcadia’s board in May 2015. Dr. Shah is president of the Rockefeller Foundation. Previously, he served as administrator of the U.S. Agency for International Development (USAID) and was undersecretary and chief scientist at the U.S. Department of Agriculture. Prior to serving in government, Dr. Shah was with the Bill & Melinda Gates Foundation for eight years. He holds a bachelor’s degree from the University of Michigan and two degrees from the University of Pennsylvania: a master’s in health economics from the Wharton School of Business and a doctorate from the School of Medicine.